NASDAQ:CCCC C4 Therapeutics (CCCC) Stock Price, News & Analysis $1.74 +0.11 (+6.75%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.75 +0.01 (+0.57%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About C4 Therapeutics Stock (NASDAQ:CCCC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get C4 Therapeutics alerts:Sign Up Key Stats Today's Range$1.65▼$1.7950-Day Range$1.10▼$2.7152-Week Range$1.09▼$7.66Volume1.14 million shsAverage Volume1.41 million shsMarket Capitalization$123.55 millionP/E RatioN/ADividend YieldN/APrice Target$12.50Consensus RatingModerate Buy Company OverviewC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Read More… C4 Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreCCCC MarketRank™: C4 Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 512th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingC4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageC4 Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about C4 Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.52) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of C4 Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of C4 Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioC4 Therapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about C4 Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.97% of the float of C4 Therapeutics has been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in C4 Therapeutics has recently decreased by 0.39%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldC4 Therapeutics does not currently pay a dividend.Dividend GrowthC4 Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.97% of the float of C4 Therapeutics has been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in C4 Therapeutics has recently decreased by 0.39%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.89 News SentimentC4 Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for C4 Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for CCCC on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, C4 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,651.00 in company stock.Percentage Held by InsidersOnly 8.55% of the stock of C4 Therapeutics is held by insiders.Percentage Held by Institutions78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about C4 Therapeutics' insider trading history. Receive CCCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CCCC Stock News HeadlinesC4 Therapeutics Inc. CCCC (U.S.: Nasdaq)May 1 at 3:40 AM | wsj.comC4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk HereMarch 10, 2025 | seekingalpha.comDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.May 4, 2025 | Weiss Ratings (Ad)C4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 1, 2025 | finanznachrichten.deStifel Nicolaus Reaffirms Their Buy Rating on C4 Therapeutics (CCCC)February 28, 2025 | markets.businessinsider.comC4 Therapeutics Full Year 2024 Earnings: EPS Beats ExpectationsFebruary 28, 2025 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Agilent (A) and C4 Therapeutics (CCCC)February 28, 2025 | markets.businessinsider.comC4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsFebruary 27, 2025 | globenewswire.comSee More Headlines CCCC Stock Analysis - Frequently Asked Questions How have CCCC shares performed this year? C4 Therapeutics' stock was trading at $3.60 at the beginning of 2025. Since then, CCCC shares have decreased by 51.7% and is now trading at $1.74. View the best growth stocks for 2025 here. How were C4 Therapeutics' earnings last quarter? C4 Therapeutics, Inc. (NASDAQ:CCCC) announced its earnings results on Thursday, February, 27th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.05. The business earned $5.18 million during the quarter, compared to analysts' expectations of $4.43 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 42.45% and a negative net margin of 313.35%. When did C4 Therapeutics IPO? C4 Therapeutics (CCCC) raised $150 million in an IPO on Friday, October 2nd 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO. Who are C4 Therapeutics' major shareholders? Top institutional investors of C4 Therapeutics include SG Americas Securities LLC (0.60%), Hennion & Walsh Asset Management Inc. (0.31%) and Rhumbline Advisers (0.13%). View institutional ownership trends. How do I buy shares of C4 Therapeutics? Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of C4 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that C4 Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings2/27/2025Today5/04/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CCCC CIK1662579 Webwww.c4therapeutics.com Phone617-231-0700FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$20.00 Low Stock Price Target$4.00 Potential Upside/Downside+618.4%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,490,000.00 Net Margins-313.35% Pretax Margin-312.52% Return on Equity-42.45% Return on Assets-27.55% Debt Debt-to-Equity RatioN/A Current Ratio6.31 Quick Ratio6.31 Sales & Book Value Annual Sales$35.58 million Price / Sales3.47 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / Book0.43Miscellaneous Outstanding Shares71,007,000Free Float64,554,000Market Cap$123.55 million OptionableOptionable Beta3.11 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:CCCC) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.